Certolizumab pegol

Nature Reviews Drug Discovery

Volumn 7, Issue 8, 2008, Pages 641-642

  Melmed, Gil Y ^a   Targan, Stephan R ^a   Yasothan, Uma ^b   Hanicq, Delphine ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IMMUNOTHERAPY; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT SELECTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TUBERCULOSIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; POLYETHYLENE GLYCOLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 48749132240     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2654     Document Type: Article

References (14)

1. Bouma, G. & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nature Rev. Immunol. 3, 521-533 (2003).
2. Korzenik, J. R. & Podolsky, D. K. Evolving knowledge and therapy of inflammatory bowel disease. Nature Rev. Drug Discov. 5, 197-209 (2006).
3. Loftus, E. V. Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126, 1504-1517 (2004).
4. Targan, S. R. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J Med. 337, 1029-1035 (1997).
5. Chang, J. T. & Lichtenstein, G. R. Drug insight: Antagonists of tumor-necrosis factor-α in the treatment of inflammatory bowel disease. Nature Clin. Pract. Gastroenterol. Hepatol. 3, 220-228 (2006).
6. Food and Drug Administration. FDA labelling information. FDA web site [online], < http://www.fda.gov/cder/foi/label/2008/ 125160s000lbl.pdf > (2008).
7. Nesbitt, A. et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor a agents. Inflamm. Bowel Dis. 13, 1323-1332 (2007).
8. Sandborn, W. J. et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357, 228-238 (2007).
9. Schreiber, S. et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357, 239-250 (2007).
10. Peyrin-Biroulet, L. et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6, 644-653 (2008).
11. Sandborn, W. J. et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann. Intern. Med. 146, 829-838 (2007).
12. Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 132, 52-65 (2007).
13. D'Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: An open randomised trial. Lancet 371, 660-667 (2008).
14. IMS Health Analysis, IMS MIDAS Quantum, MAT (2007).